CERo submits complete response letter to FDA clinical hold for CERO-1236; clinic entry now expected early 2025

CERO THERAPEUTICS HOLDINGS, INC.

Submitted complete response to FDA clinical hold on CERO-1236; 30-day review cycle expected.
Adjusted clinical trial entry from 2024 to early 2025 based on FDA timeline.
Cash balance of $3.2M as of Sept 30, 2024, sufficient for near-term strategy execution.
Al Kucharchuk appointed CFO; Kristen Pierce promoted to Chief Development Officer.
Board of Directors changes made to enhance business plan execution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.